Toward a Single-Dose Cure for Buruli Ulcer
Thomas SS, Kalia NP, Ruf MT, Pluschke G, Pethe K
Antimicrobial agents and chemotherapy · 2020-08
Abstract
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
MeSH terms
- Animals
- Mice
- Mycobacterium ulcerans
- Tuberculosis
- Disease Models, Animal
- Buruli Ulcer